Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$68.71 USD
-2.51 (-3.52%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $68.70 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CDTX 68.71 -2.51(-3.52%)
Will CDTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDTX
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
Other News for CDTX
Cidara's Flu Drug: A Phase 2 Triumph, A Phase 3 Gauntlet
CDTX makes New 52 Week High on September 19
CDTX makes New 52 Week Closing High on September 18
Is CDTX likely to continue higher? 20 Day Moving Average Support shows up after rising 0.22%
Cidara Therapeutics (CDTX) Unveils Promising Data on Influenza Drug at ISRV Conference